Enhanced reimbursement for voluntary Cancer Care Quality program to be discontinued effective December 31, 2022

Effective December 31, 2022, the enhanced reimbursement billing opportunity (S-codes) for medical oncologists selecting on-pathway drug regimens as part of the AIM Specialty Health_®* Medical Oncology Solution/ Cancer Care Quality Program (CCQP) chemotherapy authorization process will be discontinued.

 

The CCQP S-codes S0353 and S0354 were activated on July 1, 2014, and have supported providers with member care coordination, and adoption of optimal, evidence-based oncology drug regimens.

 

The CCQP/AIM pathways will continue to enable the delivery of clinically appropriate cancer treatment, and supportive medication that ensures members receive high-quality, patient-centered care. The AIM pathways will remain available to medical oncologists and related subspeciality providers via the AIM provider website.

 

As the CCQP continues to evolve, the program will become a key component of more comprehensive value-based cancer care improvement initiatives, including the Oncology Medical Home Plus (OMH+) program, launching on July 1, 2022, and January 1, 2023.

 

Contact your Anthem Blue Cross network representative or your oncology provider engagement liaison for more information.

CABC-COMM-001614-22